Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer

Ezra EW Cohen; Kathleen N Moore; Brian M Slomovitz; Christine H Chung; Matthew L Anderson; Shannon R Morris; David Mauro; Barbara Burtness

首页> 外文期刊>Journal for ImmunoTherapy of Cancer >Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer

【24h】

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer

机译：复发/转移性宫颈或人乳头瘤病毒（HPV）阳性头颈癌患者单独或联合使用ADXS11-001或MEDI4736免疫疗法的I / II期研究

获取原文

获取外文期刊封面封底 >>

开具论文收录证明 >>

文献代查 >>

团队文献服务 >>

页面导航

著录项
相似文献
相关主题

著录项

来源
《Journal for ImmunoTherapy of Cancer 》 |2015年第s2期| 共页
作者
Ezra EW Cohen; Kathleen N Moore; Brian M Slomovitz; Christine H Chung; Matthew L Anderson; Shannon R Morris; David Mauro; Barbara Burtness;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种
中图分类肿瘤学 ;
关键词

相似文献

外文文献
中文文献
专利

1. ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer [J] . Robert G Petit, Ajay Mehta, Minish Jain, Journal for ImmunoTherapy of Cancer . 2014 ,第S3期

机译：针对HPV-E7的ADXS11-001免疫疗法：针对患有复发性宫颈癌的印度女性进行的II期研究的最终结果
2. 8517 Phase I results from an open-label, randomized, controlled, phase I/II study (ADVANTAGE) to evaluate the combination of different cilengitide regimens with cisplatin, 5-FU, and cetuximab in patients with recurrent/metastatic squamous cell cancer of the head and neck (SCCHN) [J] . T.Brümmendorf, J.Guigay, R.Mesía, European Journal of Cancer Supplements . 2009 ,第2期

机译：8517期I期来自一项开放标签，随机，对照的I / II期研究（ADVANTAGE），用于评估复发/转移性鳞状细胞癌患者中不同cilengitide方案与顺铂，5-FU和西妥昔单抗的组合头和脖子（SCCHN）
3. Phase III trial of modulation of cisplatin/fluorouracil chemotherapy by interferon alfa-2b in patients with recurrent or metastatic head and neck cancer. Head and Neck Interferon Cooperative Study Group. [J] . Schrijvers D, Johnson J, Jiminez U, Journal of Clinical Oncology . 1998 ,第3期

机译：复发性或转移性头颈癌患者中通过干扰素α-2b调节顺铂/氟尿嘧啶化疗的III期试验。头颈干扰素合作研究组。
4. Proteomic identification of head and neck cancer patients with persistent human papillomavirus infections associated with improved survival [C] . Nicolas Schlecht, Nicole Kawachi, Yanhua Wang, ASMS Conference on Mass Spectrometry and Allied Topics . 2015

机译：持续人乳头瘤病毒感染的头颈癌患者蛋白质组学鉴定与提高生存相关
5. A Multiplexed Human Papillomavirus (HPV) 16 and 18 Diagnostic for Cervical Cancer Screening [D] . Wong, Winnie S. 2019

机译：多重人类乳头瘤病毒（HPV）16和18诊断宫颈癌筛查
6. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer [O] . Ezra EW Cohen, Kathleen N Moore, Brian M Slomovitz, 2015

机译：复发/转移性宫颈或人乳头瘤病毒（HPV）阳性头颈癌患者单独或联合使用ADXS11-001或MEDI4736免疫疗法的I / II期研究
7. Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer [O] . 2015

机译：复发/转移性宫颈或人乳头瘤病毒（HPV）阳性头颈癌患者单独或联合使用ADXS11-001或MEDI4736免疫疗法的I / II期研究

Phase I/II study of ADXS11-001 or MEDI4736 immunotherapies alone and in combination, in patients with recurrent/metastatic cervical or human papillomavirus (HPV)-positive head and neck cancer

著录项

相似文献

相关主题

期刊订阅